厚而弥漫的脑池血凝块可独立预测动脉瘤性蛛网膜下腔出血后血管痉挛相关并发症及不良预后
结果显示,厚而弥漫出血患者6周血管痉挛相关并发症发生率为36.1%,无此表现者为14.7%;12周不良临床结局(GOSE≥4)分别为32.7%和16.2%。厚而弥漫出血和入院WFNS分级独立预测血管痉挛相关并发症及12周不良结局。
要点
- 厚而弥漫的脑池血凝块(≥4mm且累及≥3个基底池)是血管痉挛相关并发症的独立预测因素。
- 此类患者6周血管痉挛相关并发症发生率为36.1%,显著高于无此表现者的14.7%。
- 12周不良临床结局(GOSE≥4)在厚而弥漫出血组为32.7%,无此表现组为16.2%。
核心结论
- 入院WFNS分级和厚而弥漫的蛛网膜下腔出血独立预测血管痉挛相关并发症及12周不良临床结局。
- 厚而弥漫脑池血凝块患者可能是未来血管痉挛治疗临床试验的重要靶向人群。
研究设计与样本
- 事后分析,汇总CONSCIOUS-2和CONSCIOUS-3随机双盲安慰剂对照3期试验的安慰剂组患者。
- 血凝块大小由中心裁定,比较厚而弥漫出血(≥4mm且累及≥3个基底池)与无此表现者。
主要发现
- 294例(51.4%)存在厚而弥漫的蛛网膜下腔出血。
- 厚而弥漫出血组较无此表现组年龄更大(中位55岁 vs 50岁),入院WFNS III-V级比例更高(24.1% vs 16.5%)。
- 6周全因死亡和血管痉挛相关并发症在厚而弥漫出血组为36.1%(95%CI 30.6%-41.8%),无此表现组为14.7%(95%CI 10.8%-19.5%)。
- 具体事件率:全因死亡7.5% vs 2.5%,新发脑梗死19.4% vs 6.8%,迟发性缺血性神经功能缺损28.2% vs 9.4%,因脑血管痉挛接受挽救治疗24.8% vs 10.8%。
- 12周不良临床结局(GOSE≥4)在厚而弥漫出血组为32.7%(95%CI 27.3%-38.3%),无此表现组为16.2%(95%CI 12.1%-21.1%)。
关键数值与推荐
- 厚而弥漫的蛛网膜下腔出血定义为入院CT上血凝块≥4mm厚且累及≥3个基底池。
- 血管痉挛相关并发症包括新发脑梗死、迟发性缺血性神经功能缺损和因脑血管痉挛接受挽救治疗。
- 不良临床结局定义为12周GOSE评分≥4。
临床怎么用
- 入院CT显示厚而弥漫脑池血凝块的患者应被视为血管痉挛相关并发症的高危人群,加强监测和预防性管理。
- 此类患者可优先纳入未来血管痉挛治疗的临床试验。
局限性
- 本研究为事后分析,来源于临床试验安慰剂组,可能存在选择偏倚。
- 仅纳入手术夹闭或血管内栓塞的患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Aneurysmal subarachnoid hemorrhage (aSAH) is associated with significant morbidity and mortality. The presence of thick, diffuse subarachnoid blood may portend a worse clinical course and outcome, independently of other known prognostic factors such as age, aneurysm size, and initial clinical grade. METHODS: In this post hoc analysis, patients with aSAH undergoing surgical clipping (n = 383) or endovascular coiling (n = 189) were pooled from the placebo arms of the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS)-2 and CONSCIOUS-3 randomized, double-blind, placebo-controlled phase 3 studies, respectively. Patients without and with thick, diffuse SAH (≥ 4 mm thick and involving ≥ 3 basal cisterns) on admission CT scans were compared. Clot size was centrally adjudicated. All-cause mortality and vasospasm-related morbidity at 6 weeks and Glasgow Outcome Scale-Extended (GOSE) scores at 12 weeks after aSAH were assessed. The effect of the thick and diffuse cisternal aSAH on vasospasm-related morbidity and mortality, and on poor clinical outcome at 12 weeks, was evaluated using logistic regression models. RESULTS: Overall, 294 patients (51.4%) had thick and diffuse aSAH. Compared to patients with less hemorrhage burden, these patients were older (median age 55 vs 50 years) and more often had World Federation of Neurosurgical Societies (WFNS) grade III-V SAH at admission (24.1% vs 16.5%). At 6 weeks, all-cause mortality and vasospasm-related morbidity occurred in 36.1% (95% CI 30.6%-41.8%) of patients with thick, diffuse SAH and in 14.7% (95% CI 10.8%-19.5%) of those without thick, diffuse SAH. Individual event rates were 7.5% versus 2.5% for all-cause death, 19.4% versus 6.8% for new cerebral infarct, 28.2% versus 9.4% for delayed ischemic neurological deficit, and 24.8% versus 10.8% for rescue therapy due to cerebral vasospasm, respectively. Poor clinical outcome (GOSE score ≥ 4) was observed in 32.7% (95% CI 27.3%-38.3%) and 16.2% (95% CI 12.1%-21.1%) of patients with and without thick, diffuse SAH, respectively. CONCLUSIONS: In a large, centrally adjudicated population of patients with aSAH, WFNS grade at admission and thick, diffuse SAH independently predicted vasospasm-related morbidity and poor 12-week clinical outcome. Patients with thick, diffuse cisternal SAH may be an important cohort to target in future clinical trials of treatment for vasospasm.
引用
- Aldrich EF, Higashida R, Hmissi A, et al. Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2020. PMID: 32442971. doi:10.3171/2020.3.JNS193400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。